History of CIRS

The CMR International Institute for Regulatory Science was established in 2002 under the auspices of CMR International Ltd. to assume the important role of providing a neutral forum in which senior executives from pharmaceutical companies, government regulatory agencies and academia could discuss current issues in an open-minded, intimate, and interactive environment.

In 2010, the Institute was reorganised as the Centre for Innovation in Regulatory Science Ltd., to reflect its maturing mission and to best address the objectives of the organisation. Further, this evolutionary change allows CIRS to more clearly distinguish its role and activities from those of CMR International Ltd. CIRS continues the original mission of the Institute while also addressing the related issue of the role of health technology assessment in the processes of developing medicines and expediting patients’ access to these therapies.

CIRS is an independent UK-based subsidiary company, forming part of the Intellectual Property and Science business of Thomson Reuters. It is governed pursuant to constitutional documents* that assure it is operated for the sole support of its activities and that CIRS cannot make distributions of any dividends to its parent company or any other entity. Any surplus generated from operations can only be applied to support CIRS activities. CIRS has its own dedicated management and advisory boards, and its funding is derived from membership dues and related activities.

*Please see the Resolutions to the Centre’s Articles of Association.